Abstracts Archive - Page 675 of 2425 - ACR Meeting Abstracts

Abstract Number: 0712 • ACR Convergence 2020
Switching from Reference to Biosimilars Does Not Reduce Efficacy and Safety in Juvenile Idiopathic Arthritis
Ilaria Maccora¹, Gabriele Simonini², Alessandra Bettiol³, Ilaria Pagnini⁴, Niccolò Lombardi⁵, Valerio Maniscalco⁶, Giada Crescioli⁵, Edoardo Marrani⁷, Roberto Bonaiuti⁵, Maria Vincenza Mastrolia⁸, Claudia Ravaldi⁹ and Alfredo Vannacci⁵, ¹Paediatric Rheumatology Unit, Anna Meyer Children's University Hospital, School of Human Health Science, Florence, Italy, Florence, Italy, ²Rheumatology Unit, Meyer Children's University Hospital, Florence; NEUROFARBA Department, University of Florence, Italy, Florence, Italy, ³2. Department of Neurosciences, Psychology, Drug Research and Child Health, Section of Pharmacology and Toxicology, University of Florence, Florence, Italy, Florence, ⁴1. Rheumatology Unit, Anna Meyer Children’s Hospital and Department of Neurosciences, Psychology, Drug Research and Child Health, Section of Paediatric, University of Florence, Florence, Italy, florence, Italy, ⁵2. Department of Neurosciences, Psychology, Drug Research and Child Health, Section of Pharmacology and Toxicology, University of Florence, Florence, Italy., Florence, Italy, ⁶1. Rheumatology Unit, Anna Meyer Children’s Hospital and Department of Neurosciences, Psychology, Drug Research and Child Health, Section of Paediatric, University of Florence, Florence, Italy., florence, Italy, ⁷University of Florence, Firenze, Italy, ⁸Rheumatology Unit, Meyer Children's University Hospital, Firenze, Italy, Florence, Toscana, Italy, ⁹3. Department of Health Sciences, University of Florence, Florence, Italy., Florence, Italy
Background/Purpose: Limited data about the use of biosimilar are available in children with Juvenile Idiopathic Arthritis (JIA). To evaluate the long-term efficacy and safety of switching…
Abstract Number: 0711 • ACR Convergence 2020
Alternative Dosing of Biologic Therapies Is Frequent Among Children with Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry
Colleen Correll¹, Peter Shrader², Anne Dennos³, Thomas Phillips², Natalie Shiff⁴, Ruud Verstegen⁵ and Timothy Beukelman⁶, ¹University of Minnesota, Minneapolis, MN, ²Duke University, Durham, ³Duke University, Durham, NC, ⁴Florida, Gainesville, FL, ⁵The Hospital for Sick Children, Toronto, ON, Canada, ⁶University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Biologic agents are integral to the treatment of juvenile idiopathic arthritis (JIA) and associated uveitis. Pediatric rheumatologists may increase the dosage of biologics beyond…
Abstract Number: 0717 • ACR Convergence 2020
Predictors of Clinical Remission in Children with Extended Oligoarticular Arthritis, Enthesitis-related Arthritis, or Psoriatic Arthritis Treated with Etanercept in the CLIPPER Studies
Jelena Vojinovic¹, Vyacheslav Chasnyk¹, Joke Dehoorne¹, Violeta Panaviene¹, Jonathan Akikusa², Tadej Avcin¹, Jeffrey Chaitow¹, Bernard Lauwerys¹, Jordi Antón¹, Inmaculada Penades¹, Berit Flato¹, Alina Boteanu³, Hans-Iko Huppertz¹, Juan Jaller¹, Daniela Graham⁴, Cecilia Borlenghi⁵, Bonnie Vlahos⁶, Chuanbo Zang⁶ and Nicolino Ruperto², ¹Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, ²PRINTO, Istituto Giannina Gaslini, Genova, Italy, ³Hospital Universitario Ramón y Cajal, Madrid, Spain, ⁴Pfizer, Groton, PA, ⁵Pfizer, New York, NY, ⁶Pfizer, Collegeville, PA
Background/Purpose: CLIPPER is an ongoing, 8-year, phase 3b, multicenter, open-label study of the safety and efficacy of etanercept in the treatment of juvenile idiopathic arthritis…
Abstract Number: 0716 • ACR Convergence 2020
Variations in Adalimumab and Etanercept Dosing in Juvenile Idiopathic Arthritis and Their Effect on Treatment Outcome: A Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry Study
Ruud Verstegen¹, Peter Shrader², Stephen Balevic³, Timothy Beukelman⁴, Colleen Correll⁵, Anne Dennos⁶, Thomas Phillips² and Brian Feldman¹, ¹The Hospital for Sick Children, Toronto, ON, Canada, ²Duke University, Durham, ³Duke University Medical Center, Durham, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵University of Minnesota, Minneapolis, MN, ⁶Duke University, Durham, NC
Background/Purpose: Different dosing strategies of adalimumab and etanercept have been used over the past decade in the treatment of juvenile idiopathic arthritis (JIA). With regards…
Abstract Number: 0722 • ACR Convergence 2020
Evaluation of Flare Rate and Tapering Strategies in Juvenile Idiopathic Arthritis
Antía García-Fernández¹, Andrea Briones-Figueroa¹, Laura Calvo-Sanz¹, África Andreu Suárez¹ and Alina Lucica Boteanu², ¹Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Spain, ²PRINTO, Istituto Giannina Gaslini, Genova, Italy
Background/Purpose: Biological treatment (BT) has changed the perspectives of Juvenile Idiopathic Arthritis (JIA) patients, but it remains unclear when and how to taper or to withdraw…
Abstract Number: 0724 • ACR Convergence 2020
Anxiety and Depressive Symptoms in Juvenile Idiopathic Arthritis (JIA) Correlate with Pain and Stress Using Patient-Reported Outcomes Measurement Information System (PROMIS®)
Danielle Fair¹, Judyann Olson², Jan Lemke¹, Stella Protopapas³, Ke Yan² and Jian Zhang², ¹Children's Wisconsin, Milwaukee, WI, ²Medical College of Wisconsin, Milwaukee, WI, ³Riley Children's Hospital at Indiana University, Indianapolis, IN
Background/Purpose: Children with chronic diseases have higher rates of mental health issues and less favorable outcomes than the general pediatric population. Children with JIA experience…
Abstract Number: 0719 • ACR Convergence 2020
Anti-adalimumab Antibodies Detection Using a Novel Peptide-based Assay in a Cohort of Pediatric Patients with Chronic Rheumatic Disorders: A Pilot Study
Edoardo Marrani¹, Hendrik Rusche², Francesco Terzani³, Elisa Peroni⁴, Feliciana Real-Fernandez⁵, Olivier Monasson⁴, Roberta Ponti⁶, Gabriele Simonini⁷, Anna Maria Papini³ and Paolo Rovero⁵, ¹University of Florence, Firenze, Italy, ²Peptlab@CY and Laboratory of Chemical Biology, Cergy-Paris University, Cergy-Pontoise,, France, ³PeptLab, Dep. Chemistry, University of Florence, Sesto FIorentino, Italy, ⁴Peptlab@CY and Laboratory of Chemical Biology, Cergy-Paris University, cergy-pontoise, France, ⁵PeptLab, Dep. NEUROFARBA, University of Florence, Firenze, Italy, ⁶Pediatric Department, University of Udine, udine, Italy, ⁷Rheumatology Unit, Meyer Children's University Hospital, Florence; NEUROFARBA Department, University of Florence, Italy, Florence, Italy
Background/Purpose: Immunogenicity and development of anti-drug antibodies have been associated with treatment failure and adverse events during biologic treatment. Anti-drug antibodies (ADAs) have been reported…
Abstract Number: 0714 • ACR Convergence 2020
Response to Abatacept in JIA Categories: Results from the PRCSG/PRINTO JIA Abatacept Phase IV Registry
Daniel J Lovell¹, Nikolay Tzaribachev², Esi Morgan³, Gabriele Simonini⁴, Thomas Griffin⁵, Ekaterina Alexeeva⁶, John Bohnsack⁷, Andrew Zeft⁸, Gerd Horneff⁹, Richard Vehe¹⁰, Valda Stanevicha¹¹, Stacey Tarvin¹², Maria Trachana¹³, Adam Huber¹⁴, Daniel Kietz¹⁵, Ilonka Orban¹⁶, Jason Dare¹⁷, Ivan Foeldvari¹⁸, Pierre Quartier¹⁹, Alyssa Dominique²⁰, Tzuyung Douglas Kou²⁰, Robert Wong²⁰, Alberto Martini²¹, Hermine Brunner³ and Nicolino Ruperto²², ¹PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Pediatric Rheumatology Research Institute, Bad Bramstedt, Germany, ³Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁴Anna Meyer Children's Hospital, Firenze, Italy, ⁵Levine Children's Hospital, Charlotte, NC, ⁶Scientific Center of Children’s Health of RAMS, Moscow, Russia, ⁷University of Utah and Primary Children's Hospital, Cincinnati, OH, ⁸Cleveland Clinic, Cleveland, OH, ⁹Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ¹⁰University of Minnesota, Minneapolis, MN, ¹¹Riga Stradins University, Riga, Latvia, ¹²Riley Children’s Health, Indianapolis, IN, ¹³Aristotle University of Thessaloniki, Thessaloníki, Greece, ¹⁴Dalhousie University, Halifax, NS, Canada, ¹⁵Children’s Hospital of Pittsburgh, Pittsburgh, PA, ¹⁶National Institute of Rheumatology and Physiotherapy, Budapest, Hungary, ¹⁷University of Arkansas for Medical Sciences, Little Rock, AR, ¹⁸Hamburg Centre for Pediatric and Adolescent Rheumatology, Hamburg, Germany, ¹⁹Necker-Enfants Malades University Hospital, Assistance Publique-Hopitaux de Paris, Paris, France, ²⁰Bristol-Myers Squibb Company, Princeton, NJ, ²¹PRINTO, Istituto Giannina Gaslini, Genova, Italy, ²²Istituto Giannina Gaslini, Genova, Italy
Background/Purpose: Abatacept, a selective T-cell co-stimulation modulator, has been demonstrated to be well tolerated and effective in JIA in 2 Phase III studies.1,2 The ongoing…
Abstract Number: 0727 • ACR Convergence 2020
Hip Involvement Leads to Poor Outcome in Adulthood in Children with Enthesitis Related Arthritis (ERA) Category of Juvenile Idiopathic Arthritis (JIA)
Naveen R¹, Namita Mohindra¹, Neeraj Jain¹ and Amita Aggarwal², ¹Sanjay Gandhi Post graduate institute of medical sciences, Lucknow, Uttar Pradesh, India, ²Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
Background/Purpose: Enthesitis related arthritis (ERA) is the commonest category of JIA seen in India and constitutes 30-40% of all JIA patients. There are many studies…
Abstract Number: 0730 • ACR Convergence 2020
To Taper or Not to Taper in Juvenile Idiopathic Arthritis: Is There a Risk of Development of Uveitis Flares?
Maria Teran¹, Alina Lucica Boteanu², Carlos Guillen¹, Cristina Pijoan¹, Jose Quinones¹, Veronica Garcia³, Ivan Del Bosque-Granero³, Laura Calvo-Sanz⁴ and Mónica Vázquez⁴, ¹Hospital Ramon y Cajal, Madrid, Madrid, Spain, ²PRINTO, Istituto Giannina Gaslini, Genova, Italy, ³Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Madrid, Spain, ⁴Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Spain
Background/Purpose: To determine the association between the occurrence of uveitis flares in patients with Juvenile Idiopathic Arthritis (JIA) and the de-intensification of immunosuppressive treatment.Methods: We…
Abstract Number: 0731 • ACR Convergence 2020
Comparing S100 Proteins and Cytokine Levels in Tears Based on Uveitis Activity Laterality in Children with JIA-associated Uveitis and Non-JIA-U
Jackeline Rodriguez-Smith¹, Virginia Miraldi Utz², Amy Cassedy¹, Sherry Thornton¹, Grant Schulert³, Alyssa Sproles⁴, Najima Mwase¹, Theresa Hennard¹, Mekibib Altaye², Alexei Grom¹ and Sheila Angeles-Han¹, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Cincinnati Children's Hospital Medical Center, Cincinnati, ³PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁴Cincinnati Children's Hospital, Cincinnati
Background/Purpose: The pathogenesis of pediatric uveitis remains unclear. Studies of biomarkers using aqueous humor (AqH) identified S100 proteins, cytokines, and chemokines as potential biomarkers of…
Abstract Number: 0726 • ACR Convergence 2020
Who Ordered the Stiff One? Characteristics of Polyarticular Juvenile Idiopathic Arthritis Patients Associated with the Presence and Increased Duration of Joint Stiffness
Nayimisha Balmuri¹, Victoria Cooley², Linda Gerber², Susan Goodman³, Bella Mehta³ and Karen Onel⁴, ¹Hospital for Special Surgery, new york, NY, ²Weill Cornell Medicine, NY, NY, ³Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁴Pediatric Rheumatology, Hospital for Special Surgery, New York, NY
Background/Purpose: Joint stiffness as a sign of intra-articular inflammation may be an early presenting symptom of JIA. Studies following pain in chronic disease have shown…
Abstract Number: 0734 • ACR Convergence 2020
Differences and Similarities Between down Syndrome-associated Arthritis and Juvenile Idiopathic Arthritis in the New Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry
Jordan Jones¹, Chelsey Smith², Daniel J Lovell³ and Mara Becker⁴, ¹Children's Mercy Kansas City, Kansas City, MO, ²Children's Mercy Kansas City, Holden, MO, ³PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁴Duke University School of Medicine, Durham, NC
Background/Purpose: Down syndrome-associated arthritis (DA) is under-recognized with delay in diagnosis (1). The majority of those with DA present with polyarticular, rheumatoid factor (RF) and…
Abstract Number: 0729 • ACR Convergence 2020
Morbidity of JIA-associated Uveitis: Half of Patients Despite Systemic Treatment Still Show Ocular Damage During a Long-term Follow-up
Francesca Minoia¹, Luca Marelli², Gisella Beatrice Beretta³, Micol Romano⁴, Elisabetta Miserocchi⁴, Chiara Mapelli³, Antonella Petaccia³, Stefano Lanni³, Irene Pontikaki⁴, Giovanni Filocamo³ and Rolando Cimaz⁵, ¹Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, Milan, Italy, ²San Giuseppe Hospital, IRCCS Multimedica, Milan, Italy, Milan, Italy, ³Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy, Milan, Italy, ⁴ASST Gaetano Pini-CTO Institute, Milan, Italy, Milan, Italy, ⁵ASST Gaetano Pini-CTO Institute and Università degli Studi di Milano, Milan, Italy, Milan, Italy
Background/Purpose: Uveitis is the most common extra-articular complication of juvenile Idiopathic arthritis (JIA). Due to its typical indolent and chronic course, children with this condition…
Abstract Number: 0621 • ACR Convergence 2020
Effectiveness of Screening in Patients with Rheumatic Disease Before Commencing Biologic Therapy and Risk of Active Tuberculosis
Sultana Abdulaziz¹, Suzan Attar², Wael Bajhammoh³, Eman Alsindi³, Eman Bakhashwain⁴ and Doaa Ayish⁵, ¹King Fahd Hospital, Jeddah, Saudi Arabia, ²King Abdulaziz University, Jeddah, Saudi Arabia, ³King Fahad Hospital, Jeddah, Saudi Arabia, ⁴East Jeddah Hospital, Jeddah, Saudi Arabia, ⁵Prince Mohammed Bin Nasser Hospital, Gizan, Saudi Arabia
Background/Purpose: Treatment with biologic therapy has been associated with a high risk of reactivation of latent tuberculosis (TB ). Preventive strategies for tuberculosis remain a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].